✨ Free AI Report
Celgene Corporation: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Celgene Corporation
Research Preview

Celgene Corporation: Business Overview, Financials & Competitive Analysis

Celgene Corporation is an American pharmaceutical company that makes cancer and immunology drugs. The company is a subsidiary of Bristol Myers Squibb (BMS) since its acquisition in 2019. Its major product is Revlimid ...

Analyst-debate audio for Celgene Corporation

AskCyborg analysts argue the bull and bear cases for Celgene Corporation across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Celgene Corporation OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
7/ 10Strong

Cyborg Score thesis

Celgene's cash-generative blockbuster franchise and advanced CAR-T pipeline provide strategic value to BMS, though lack of...

Read the full analyst-debate transcript →
Industry Oncology Drugs
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Celgene Corporation Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Celgene Corporation Overview

Pro stress-test →

Celgene Corporation is an American pharmaceutical company that makes cancer and immunology drugs. The company is a subsidiary of Bristol Myers Squibb (BMS) since its acquisition in 2019. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias.

Strategic Profile

Pro stress-test →

As of February 2026, Celgene's annual revenue is estimated to be $21B. The company is developing therapies for multiple myeloma, inflammatory diseases, and various forms of cancer, with its lead molecule BCMA CAR T used for treating multiple myeloma in phase II clinical study. As a wholly-owned subsidiary integrated into Bristol Myers Squibb's oncology and immunology divisions, Celgene remains a critical driver of BMS's cancer therapeutics portfolio.

Competitive Landscape

Pro stress-test →

Top competitors include Kite Pharma, Juno Therapeutics and ImmunoACT. Celgene competes in the immunotherapy and cancer drug markets alongside major pharma innovators developing CAR-T therapies and next-generation immuno-oncology agents. Within Bristol Myers Squibb's portfolio, Celgene's oncology franchise complements BMS's broader immunology and cardiovascular platforms.

Industry Context

Celgene Corporation operates in Oncology Drugs.

Key facts

Founded: 1986 · Headquarters: Summit, New Jersey, US · Employees: 2,100 · Revenue: $21B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Celgene Corporation.

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Celgene Corporation has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Kite PharmaCAR-T cell therapy and oncology focus→Juno TherapeuticsCell therapy and hematologic malignancy focus→ImmunoACTImmunotherapy development→RevlimidImmunomodulatory drug for multiple myeloma→

Compare Celgene Corporation with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Celgene Corporation operates in Oncology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology Drugs research →
NEW · MCP server

Ask your AI assistant about Celgene Corporation

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Celgene Corporation and its top competitor on Cyborg Score”
“What did Celgene Corporation do this quarter?”
“Is Celgene Corporation a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Celgene Corporation do?+
Celgene Corporation is an American pharmaceutical company that makes cancer and immunology drugs. The company is a subsidiary of Bristol Myers Squibb (BMS) since its acquisition in 2019. Its major product is Revlimid ...
What is Celgene Corporation's Cyborg Score?+
Celgene Corporation has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Celgene Corporation's main competitors?+
Named competitors include Kite Pharma, Juno Therapeutics, ImmunoACT, Revlimid. The full competitive landscape is in the AskCyborg report.
How can I get the full Celgene Corporation research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Celgene Corporation research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Celgene Corporation over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.